Injectable host-guest gel nanovaccine for cancer immunotherapy against melanoma
Source abstract
Abstract
Despite the extensive development of peptide-based tumor antigen vaccines, the field still faces up enormous challenges from lacking clinical efficacy. Here, we report the design and development of a therapeutic nanovaccine for cancer immunotherapy by using gold nanoparticle (AuNPs)-conjugated peptides for incorporation with a supramolecular hydrogel, and via the featured host-guest interactions to carry and deliver select antigen peptides in conjunction with unmethylated cytosine-guanine oligodeoxynucleotide (CpG). The injectable nanovaccine shows significant improvement on the spatial draining lymph nodes (dLNs) delivery of the antigen peptides in antigen presenting cells (APCs) in vivo. Administration of the hydrogel nanovaccine results in a remarkable enhancement of the peptide uptake by APCs in the dLNs with a subsequent induction of the antigen-specific cytotoxic T lymphocytes (CTL) in the periphery, which is in association with 4 to 8-fold increases of these CTLs infiltrating in the tumor tissues. Finally, vaccination with the AuNPs-featured OVAp hydrogel presents with significant retardation of tumor progression that improves the survival rates in mice bearing established B16-OVA melanoma, indicating good efficacy in treating malignant cancers. Together, these findings offer a new strategy for development of spatiotemporally efficient antigen-peptide therapeutic nanovaccine for cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (85)
Show source-provided references
1. Enhancing cancer immunotherapy with nanomedicine10.1038/s41577-019-0269-6 ↗
2. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
3. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines10.1038/nrc2373 ↗
4. Peptide vaccines for cancer10.1081/CNV-120001149 ↗
5. Vaccines for established cancer: overcoming the challenges posed by immune evasion10.1038/nrc.2016.16 ↗
6. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment10.1038/nri1995 ↗
7. Therapeutic potential of Toll-like receptor 9 activation10.1038/nrd2059 ↗
8. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma10.1200/JCO.2006.07.9129 ↗
9. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors10.1038/ni.1863 ↗
10. TLR9 as a key receptor for the recognition of DNA10.1016/j.addr.2007.12.004 ↗
11. Folic acid-CdTe quantum dot conjugates and their applications for cancer cell targeting10.1007/s12645-010-0003-3 ↗
12. X-ray induced photodynamic therapy with copper-cysteamine nanoparticles in mice tumors10.1073/pnas.1900502116 ↗
13. Active targeting of nano-photosensitizer delivery systems for photodynamic therapy of cancer stem cells10.1166/jbn.2015.2090 ↗
14. A STING-activating nanovaccine for cancer immunotherapy10.1038/nnano.2017.52 ↗
15. Design and fabrication of drug-delivery systems toward adjustable release profiles for personalized treatment10.1002/VIW.20200126 ↗
16. Cytomembrane infused polymer accelerating delivery of myelin antigen peptide to treat experimental autoimmune encephalomyelitis10.1021/acsnano.8b06575 ↗
17. A STING-activating nanovaccine for cancer immunotherapy10.1038/nnano.2017.52 ↗
18. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy10.1016/j.biomaterials.2013.04.007 ↗
19. Noninvasive transdermal vaccination using hyaluronan nanocarriers and laser adjuvant10.1002/adfm.201504879 ↗
20. Programmable hydrogels10.1016/j.biomaterials.2018.03.008 ↗
21. Nanoparticle-programmed surface for drug release and cell regulation via reversible hybridization reaction10.1021/acsami.6b14355 ↗
22. Programmable hydrogels for the controlled release of therapeutic nucleic acid aptamers via reversible DNA hybridization10.1039/c3cc45594g ↗
23. Aptamer-functionalized hydrogel for self-programmed protein release via sequential photoreaction and hybridization10.1021/acs.chemmater.7b00875 ↗
24. Injectable, guest–host assembled polyethylenimine hydrogel for siRNA delivery10.1021/acs.biomac.6b01378 ↗
25. Sustained small molecule delivery from injectable hyaluronic acid hydrogels through host–guest mediated retention10.1039/C5TB00981B ↗
26. Shear-thinning and self-healing hydrogels as injectable therapeutics and for 3D-printing10.1038/nprot.2017.053 ↗
27. Cyclodextrin-responsive micelles based on poly (ethylene glycol)–polypeptide hybrid copolymers as drug carriers10.1021/mz300568b ↗
28. Rational design of network properties in guest–host assembled and shear-thinning hyaluronic acid hydrogels10.1021/bm401280z ↗
29. Complex formation between poly (ethylene glycol) and α-cyclodextrin10.1021/ma00212a039 ↗
30. Polypseudorotaxanes and polyrotaxanes10.1016/j.progpolymsci.2005.07.003 ↗
31. Cyclodextrin-based host–guest supramolecular hydrogel and its application in biomedical fields10.1039/C8PY00730F ↗
32. Preparation and properties of inclusion complexes of polyethylene glycol with. alpha.-cyclodextrin10.1021/ma00073a026 ↗
33. Redox-generated mechanical motion of a supramolecular polymeric actuator based on host–guest interactions10.1002/anie.201300862 ↗
34. Bioactive supramolecular hydrogel with controlled dual drug release characteristics10.1021/bm100676a ↗
35. Mechanically resilient, injectable, and bioadhesive supramolecular gelatin hydrogels crosslinked by weak host-guest interactions assist cell infiltration and in situ tissue regeneration10.1016/j.biomaterials.2016.05.043 ↗
36. Alpha-cyclodextrin turns SDS-induced amyloid fibril into native-like structure10.1016/j.molliq.2019.111090 ↗
37. Supramolecular hydrogels based on poly (ethylene glycol)-poly (lactic acid) block copolymer micelles and α-cyclodextrin for potential injectable drug delivery system10.1016/j.carbpol.2018.04.035 ↗
38. Specific Modification with TPGS and Drug Loading of cyclodextrin polyrotaxanes and the enhanced antitumor activity study in vitro and in vivo10.1021/acsami.9b14075 ↗
39. Drug carriers for the delivery of therapeutic peptides10.1021/bm500169p ↗
40. Uptake of engineered gold nanoparticles into mammalian cells10.1021/cr300441a ↗
41. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells10.1186/s12951-018-0362-1 ↗
42. A multidentate peptide for stabilization and facile bioconjugation of gold nanoparticles10.1021/bc8003028 ↗
43. Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial smad2/3 signaling10.1021/acsnano.9b08460 ↗
44. Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8+ T cell responses10.1021/acsnano.5b07716 ↗
45. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo10.1021/nn3057005 ↗
46. Dendritic cell-based nanovaccines for cancer immunotherapy10.1016/j.coi.2013.03.001 ↗
47. Pathogen-mimicking polymeric nanoparticles based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses10.1002/smll.201503662 ↗
48. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment10.1021/nl300027p ↗
49. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions10.1038/physci241020a0 ↗
50. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice10.1002/eji.201948225 ↗
51. Analysis of functionalization of methoxy–PEG as maleimide–PEG10.1016/j.ab.2007.11.034 ↗
52. Synthesis of poly (ethylene glycol)-tethered poly (propylene fumarate) and its modification with GRGD peptide10.1016/S0032-3861(00)00117-8 ↗
53. Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging
54. Tumor-targeting peptide functionalized PEG-PLA micelles for efficient drug delivery10.1039/C9BM02036E ↗
55. Quality control of therapeutic peptides by 1H NMR HiFSA sequencing10.1021/acs.joc.8b02704 ↗
56. PEGylation of Melittin: structural characterization and hemostatic effects10.1177/0883911509354230 ↗
57. A PEG-Lysozyme hydrogel harvests multiple functions as a fit-to-shape tissue sealant for internal-use of body10.1016/j.biomaterials.2018.10.047 ↗
58. Probing the molecular structure of antimicrobial peptide-mediated silica condensation using X-ray photoelectron spectroscopy10.1039/c2jm30837a ↗
59. Characterization of the Ca 2+-coordination structures of L-and T-plastins in combination with their synthetic peptide analogs by FTIR spectroscopy10.1038/s41598-019-40889-9 ↗
60. Insights into the molecular architecture of a peptide nanotube using FTIR and solid-state NMR spectroscopic measurements on an aligned sample10.1002/ange.201301960 ↗
61. Rational and combinatorial design of peptide capping ligands for gold nanoparticles10.1021/ja0487269 ↗
62. Aggregation behavior of nanoparticle-peptide systems affects autophagy10.1021/acs.bioconjchem.9b00266 ↗
63. Impact of the nanoparticle–protein corona on colloidal stability and protein structure10.1021/la301104a ↗
64. Viscosity and degradation controlled injectable hydrogel for esophageal endoscopic submucosal dissection
65. Tough but self-healing and 3D printable hydrogels for E-skin, E-noses and laser controlled actuators10.1039/C9TA04248B ↗
66. Sol–gel transition during inclusion complex formation between α-cyclodextrin and high molecular weight poly (ethylene glycol) s in aqueous solution10.1295/polymj.26.1019 ↗
67. The molecular necklace: a rotaxane containing many threaded α-cyclodextrins10.1038/356325a0 ↗
68. Introduction and general overview of cyclodextrin chemistry10.1021/cr970022c ↗
69. Branched polyrotaxane hydrogels consisting of alpha-cyclodextrin and low-molecular-weight four-arm polyethylene glycol and the utility of their thixotropic property for controlled drug release10.1016/j.colsurfb.2018.02.032 ↗
70. Egg albumen as a fast and strong medical adhesive glue10.1002/adhm.201700132 ↗
71. Localization, quantitation, and in situ detection of specific peptide–MHC class I complexes using a monoclonal antibody10.1016/S1074-7613(00)80447-1 ↗
72. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation10.1126/science.1137971 ↗
73. Functions of natural killer cells10.1038/ni1582 ↗
74. Gold nanoparticle mediated cancer immunotherapy10.1016/j.nano.2013.09.011 ↗
75. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
76. Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy10.1021/acsnano.9b06691 ↗
77. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates10.1158/2326-6066.CIR-13-0223 ↗
78. Synthesis of gold nanoparticle: peptide–drug conjugates for targeted drug delivery
79. Ribbon of DNA lattice on gold nanoparticles for selective drug delivery to cancer cells10.1002/anie.202005624 ↗
80. Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein− Barr virus-specific cytotoxic T-Lymphocyte responses in vitro10.1021/bc800167q ↗
81. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro10.1186/1556-276X-8-72 ↗
82. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells
83. Monolayer coated gold nanoparticles for delivery applications10.1016/j.addr.2011.08.006 ↗
84. Probing the aggregation and immune response of human islet amyloid polypeptides with ligand-stabilized gold nanoparticles10.1021/acsami.8b19506 ↗
85. Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment10.1021/acs.nanolett.9b03968 ↗